

Brand Institute is proud to have partnered with 900+ healthcare companies on over 3,300 pharmaceutical brand names, highlighted by these most recent name approvals from Health Canada

PLEASE BE SAFE AND THANK YOU FOR MAKING
 BRAND INSTITUTE THE WORLD'S #1 NAMING COMPANY!

December 17, 2020  increlex® (mecasermin) injection 10 mg IPSEN BIOPHARMACEUTICALS	December 15, 2020  zolgensma® (onasemnogene abeparvovec-xioi) NOVARTIS	November 25, 2020  Tirosint® (levothyroxine sodium) capsules IBSA INSTITUT BIOCHEMIQUE
November 24, 2020  Hulio® (adalimumab) BGP PHARMA	November 19, 2020  Tavalisse® (fostamatinib disodium hexahydrate) tablets RIGEL PHARMACEUTICALS	November 19, 2020  PERSERIS® (risperidone) for extended-release injectable suspension HLS THERAPEUTICS
November 18, 2020 Tri-Cira 21 Tri-Cira 28 APOTEX	November 5, 2020 Inclunox enoxaparin SANDOZ	November 5, 2020 Inclunox HP enoxaparin SANDOZ
November 4, 2020  DAYVIGO (lemborexant) (V) 5mg, 10mg tablets EISAI	November 4, 2020  Hyrimoz® adalimumab SANDOZ	November 4, 2020  AMGEVITA (adalimumab) AMGEN

DRUG SAFETY INSTITUTE (DSI) NAMING & LABELING EXPERT SPOTLIGHT



Scott Sawler, B.Sc., LL.B., LL.M., M.B.A.


President, Canadian Regulatory Affairs
 Drug Safety Institute

Mr. Sawler joined Brand Institute's regulatory subsidiary, Drug Safety Institute (DSI) - Ottawa as Managing Director, Canadian Regulatory Affairs in 2017 and in 2018 was promoted to President, Canadian Regulatory Affairs. Prior to joining DSI, he was Director General (DG) of Health Canada's Marketed Health Products Directorate (MHPD), which is responsible for reviewing and approving proposed proprietary (brand) names; conducting risk/benefit assessments of marketed health products; overseeing the advertising regulatory requirements of health products; providing policies to effectively regulate marketed health products etc.

Prior to this, Mr. Sawler was the DG of Health Canada's Natural and Non-prescription Health Product Directorate where he led the program through a transitional period. He re-established its strategic vision, overhauled its policies and streamlined management systems to put the program back on track. Mr. Sawler also has significant experience as an executive and counsel in clinical trial management, government, legal and regulatory affairs. His clients included pharmaceutical companies, health professional associations, and non-governmental organizations.

Mr. Sawler earned his LL.M. from Osgoode Hall at York University, an M.B.A. from the University of Laval, an LL.B. from the University of Ottawa, and a B.Sc. in Chemistry from the University of New Brunswick.

BRAND INSTITUTE'S 2020 GLOBAL SHARE OF MARKET NAME APPROVALS



Corporate Headquarters

200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL +41 78-879-4619	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49 6196-400-966	LONDON +44 207-240-2200	LOS ANGELES (310) 830-6111	MIAMI (305) 984-6889	NEW YORK (212) 557-2100
OTTAWA (613) 482-1333	RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SÃO PAULO +55 11 945-364-083	SEATTLE (206) 204-5111	SEOUL +82 6433-9555	TOKYO +81(03) 6861-7517	TORONTO (416) 622-5777